Camostat mesylate, initially developed for pancreatitis, and nafamostat have exhibited efficiency in blocking TMPRSS2-mediatedSARS-CoV-2 entry, with continuing clinical trials examining its effectiveness against COVID-19, demonstrating potential antiviral characteristics against the virus [152]. This evidence concerns the gene TMPRSS2 and COVID-19.